Evaxion Expands AI-Immunology Platform Into Autoimmune Disease
COPENHAGEN, Denmark — September 14, 2026 Evaxion A/S announced that it has begun applying its proprietary AI-Immunology™ platform to...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
COPENHAGEN, Denmark — September 14, 2026 Evaxion A/S announced that it has begun applying its proprietary AI-Immunology™ platform to...
COPENHAGEN, Denmark, August 14, 2026 Evaxion A/S (NASDAQ: EVAX) is preparing to provide a business update and second-quarter 2026...
